Article
LCP1 is a potential prognostic biomarker and correlates with immune infiltration in triple negative breast cancer
2024-03-28
Abstract excerpt
<h4>Objective: </h4> Triple-Negative Breast Cancer (TNBC), known for its aggressiveness and treatment challenges due to the absence of ER, PR, and HER2 receptors, is the focus of this study. The research emphasizes the need for new biomarkers like LCP1 (Lymphocyte cytosolic protein 1), which plays a crucial role in cell processes and immune cell activity, to predict outcomes and guide treatments in TNBC. Methods...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 3c719d38-fef3-5989-abd6-483bf1dd0314
- DOI
- 10.21203/rs.3.rs-4090958/v1
